Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Agreement to develop E. coli O157:H7 vaccine
Researchers at work on the project in the Roslin Institute
Collaborative research enters commercial phase

Roslin Technologies has signed an agreement with animal sciences research establishments Moredun Research Institute, Scotland’s Rural College and the Roslin Institute at the University of Edinburgh, to fund the commercial development of an E. coli O157:H7 vaccine for cattle, which it is claimed will prevent illness in humans.

E. coli O157:H7 is a pathogenic bacterium of cattle that can cause life-threatening food-borne illness in humans through the consumption of contaminated products, such as dairy products and meat. Despite efforts to reduce contamination of food, E. coli O157:H7 causes one to 10 cases per 100,000 people, with certain countries having clusters of more virulent strains – notably the UK, USA, Argentina and Sweden.
 
The experimental vaccine has been developed to limit E. coli O157:H7 shedding from – and transmission between – cattle. Although the bacteria do not harm cattle, farmers will be encouraged to vaccinate animals against infection with this new vaccine. Early results have indicated that this vaccine may be more effective than other previous attempts and have a greater impact in reducing human exposure and infection.

The project team has been led by Dr Simon Wheeler COO of Roslin Technologies, with significant input from the principal investigators, Professor David Gally from Roslin Institute and Dr Tom McNeilly from Moredun Research Institute, who have been doing the fundamental research necessary to really understand whether the vaccine works and the essential science behind it.

Under the new agreement, Roslin Technologies will perform a two-step validation trial from May  to September 2020 in Nebraska, USA. The field trials will examine ‘super-shedding’ in cattle to discover whether the vaccine prevents shedding of the bacteria and is viable for commercial use.
 
The background research was funded  in part by UK agencies Defra (Department for Environment, Food & Rural Affairs), BBSRC (Biotechnology and Biological Sciences Research Council, FSA/FSS (Food Standards Agency/Food Standards Scotland), and other commercial partners. This valuable contribution is recognised by the project team.

Become a member or log in to add this story to your CPD history

Applications open for MMI research grants

News Story 1
 RCVS' Mind Matters Initiative (MMI) has launched round two of its veterinary mental health research grants.

Researchers have until 11.59pm on Wednesday, 28 May 2025 to apply for a grant for research which reflects MMI's 2025 focus areas.

Only one Impact Grant was awarded last year, and so this year there are two Discovery Grants and one Impact Grants available. Each Discovery Grant is worth £5,000 and the Impact Grant is worth £15,000.

For more information or to apply, email researchgrants@rcvs.org.uk to contact the MMI team.

 

Click here for more...
News Shorts
Germany livestock import ban lifted

The UK government has amended its ban on the import of livestock, meat and dairy products from Germany.

Defra said the decision follows 'rigorous technical assessment' of the measures applied and the current situation. "If the situation changes, we will not hesitate to take necessary action in response to the FMD outbreaks in the European Union to protect our domestic biosecurity," it said.

The ban was implemented in January following an outbreak of foot and mouth disease (FMD) near Berlin. Personal imports of meat, milk and dairy products will remain in place at a country level.